DICERNA — 1929867
Application number
1929867
Registration number
TMA1154694
Type(s)
Standard Characters
Category
Trademark
CIPO Status
REGISTERED
TM5 status
LIVE/REGISTRATION/Issued
and Active
The trademark application has been registered with the Office.
Filed
2018-11-09
Registered
2022-12-05
Registration Expiry Date
2032-12-05
Registered Owner
Dicerna Pharmaceuticals, Inc.
87 Cambridgepark Drive
Cambridge, MA 02140
UNITED STATES OF AMERICA
Agent
CPST INTELLECTUAL PROPERTY INC.
130 Queens Quay East
East Tower, Suite 809
Toronto,
ONTARIO M5A0P6
Documents
Index headings
- DICERNA
Goods (Nice class & Statement)
- 5
- (1) Pharmaceutical preparations for the treatment of various diseases, namely, rare metabolic, endocrine, cardiac, oncological, gastrointestinal, nephrological, autoimmune, and neurological diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Oligonucleotide compounds for use in the targeted delivery of RNAi therapy; Pharmaceutical preparations for use in targeted pharmaceutical therapies for the treatment of various diseases, namely, rare metabolic, endocrine, cardiac, oncological, gastrointestinal, nephrological, autoimmune, and neurological diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Chemical compounds in the form of a molecular nanoparticle complex that act as a platform for the delivery of RNA-based drugs to biological cells; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies
Services (Nice class & Statement)
- 42
- (1) Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; research and development of pharmaceutical preparations for the treatment of liver-based disorders; research and development of oligonucleotide compounds for targeted gene silencing; scientific research and development for the treatment of various diseases, namely rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, and cancers and viral infections; scientific investigations in the fields of rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, and cancers and viral infections for medical purposes; providing medical and scientific research information in the field of pharmaceuticals and clinical trials
Claims
- Priority Filing Date: May 16, 2018, Country or Office: UNITED STATES OF AMERICA, Application No. 87/924,237 in association with the same kind of goods and in association with the same kind of services
Action History
| Action | Action date | Due date | Comments |
|---|---|---|---|
| Filed | 2018-11-09 | ||
| Created | 2018-11-13 | ||
| Formalized | 2018-11-15 | ||
| Search Recorded | 2021-05-14 | ||
| Examiner's First Report | 2021-05-14 | 2021-11-14 | |
| Agent Changed | 2021-10-20 | From: 92 To: 23264 / Voir Preuve au dossier/See evidence on File No. 1929863 | |
| Default Notice Sent | 2021-12-29 | 2022-02-28 | |
| Default Removed | 2022-01-26 | ||
| Approved | 2022-02-01 | APPROVED BY PROGRAM EX200M1 | |
| Approval Notice Sent | 2022-02-01 | APPROVED BY PROGRAM EX200M1 | |
| Advertised | 2022-04-13 | Vol.69 Issue 3520 | |
| Registration Pending | 2022-08-24 | ||
| Registration Fee Notice Sent | 2022-08-24 | 2023-02-24 | |
| Registered | 2022-12-05 | 2032-12-05 |